These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
110 related articles for article (PubMed ID: 17603707)
1. The potential mechanism of chemosensitive difference between 2 types of ovarian cancer. He X; Lin B; Kong L; Zhang J Saudi Med J; 2007 Jul; 28(7):1044-9. PubMed ID: 17603707 [TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical and two-parameter flow cytometric studies of DNA topoisomerase II alpha in human epithelial ovarian carcinoma and germ cell tumor. Tanoguchi K; Sasano H; Yabuki N; Kikuchi A; Ito K; Sato S; Yajima A Mod Pathol; 1998 Feb; 11(2):186-93. PubMed ID: 9504690 [TBL] [Abstract][Full Text] [Related]
3. The association between the p53/topoisomerase I and p53/ topoisomerase IIalpha immunophenotypes and the progression of ovarian carcinomas. Bar JK; Grelewski P; Noga L; Rabczyński J; Gryboś M; Jeleń M Adv Clin Exp Med; 2012; 21(1):35-42. PubMed ID: 23214297 [TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical expression of topoisomerase IIalpha (Topo IIalpha) and multidrug resistance-associated protein (MRP), plus chemosensitivity testing, as chemotherapeutic indices of ovarian and endometrial carcinomas. Koshiyama M; Fujii H; Kinezaki M; Morita Y; Nanno H; Yoshida M Anticancer Res; 2001; 21(4B):2925-32. PubMed ID: 11712788 [TBL] [Abstract][Full Text] [Related]
5. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas]. Shao HL; Shen DH; Xue WC; Li Y; Yu YZ Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760 [TBL] [Abstract][Full Text] [Related]
6. Type IV collagen and CD44v6 expression in benign, malignant primary and metastatic ovarian tumors: correlation with Ki-67 and p53 immunoreactivity. Bar JK; Grelewski P; Popiela A; Noga L; Rabczyñski J Gynecol Oncol; 2004 Oct; 95(1):23-31. PubMed ID: 15385106 [TBL] [Abstract][Full Text] [Related]
7. Expression of DNA topoisomerase I and DNA topoisomerase II-alpha in carcinoma of the colon. Staley BE; Samowitz WS; Bronstein IB; Holden JA Mod Pathol; 1999 Apr; 12(4):356-61. PubMed ID: 10229499 [TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical staining for DNA topoisomerase I, DNA topoisomerase II-alpha and p53 in gastric carcinomas. Coleman LW; Bronstein IB; Holden JA Anticancer Res; 2001; 21(2A):1167-72. PubMed ID: 11396158 [TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma. Tomsová M; Melichar B; Sedláková I; Steiner I Gynecol Oncol; 2008 Feb; 108(2):415-20. PubMed ID: 18037158 [TBL] [Abstract][Full Text] [Related]
10. Correlation between Topo II alpha expression and chemosensitivity testing for Topo II-targeting drugs in gynaecological carcinomas. Koshiyama M; Fujii H; Kinezaki M; Yoshida M Anticancer Res; 2001; 21(2A):905-10. PubMed ID: 11396183 [TBL] [Abstract][Full Text] [Related]
11. P-glycoprotein expression and DNA topoisomerase I and II activity in benign tumors of the ovary and in malignant tumors of the ovary, before and after platinum/cyclophosphamide chemotherapy. van der Zee AG; Hollema H; de Jong S; Boonstra H; Gouw A; Willemse PH; Zijlstra JG; de Vries EG Cancer Res; 1991 Nov; 51(21):5915-20. PubMed ID: 1682037 [TBL] [Abstract][Full Text] [Related]
12. Expression and relationship between topoisomerase I and II alpha genes in tumor and normal tissues in esophageal, gastric and colon cancers. Kim R; Ohi Y; Inoue H; Toge T Anticancer Res; 1999; 19(6B):5393-8. PubMed ID: 10697567 [TBL] [Abstract][Full Text] [Related]
13. Topoisomerase II alpha expression correlates with diminished disease-free survival in invasive breast cancer. O'Connor JK; Hazard LJ; Avent JM; Lee RJ; Fischbach J; Gaffney DK Int J Radiat Oncol Biol Phys; 2006 Aug; 65(5):1411-5. PubMed ID: 16750309 [TBL] [Abstract][Full Text] [Related]
14. A review of p53 expression and mutation in human benign, low malignant potential, and invasive epithelial ovarian tumors. Kmet LM; Cook LS; Magliocco AM Cancer; 2003 Jan; 97(2):389-404. PubMed ID: 12518363 [TBL] [Abstract][Full Text] [Related]
15. Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer. Goodell V; Salazar LG; Urban N; Drescher CW; Gray H; Swensen RE; McIntosh MW; Disis ML J Clin Oncol; 2006 Feb; 24(5):762-8. PubMed ID: 16391298 [TBL] [Abstract][Full Text] [Related]
16. [Expression of KiSS-1, matrix metalloproteinase-9, nuclear factor-kappaBp65 in ovarian tumour]. Gao GL; Liu LD; Zou XS; Chen WX Zhonghua Fu Chan Ke Za Zhi; 2007 Jan; 42(1):34-8. PubMed ID: 17331419 [TBL] [Abstract][Full Text] [Related]
17. Comparative topoisomerase IIa and ki 67 protein expression in papillary thyroid carcinoma based on tissue microarrays and image analysis. Manaios L; Tsiambas E; Alevizaki M; Karameris A; Alexopoulou D; Lambropoulou S; Moreas H; Kravvaritis C; Fotiades PP; Goula K; Patsouris E; Athanassiou AE; Koutras D; Katsilambros N J BUON; 2008; 13(4):537-41. PubMed ID: 19145676 [TBL] [Abstract][Full Text] [Related]
18. Altered expression pattern of topoisomerase IIalpha in ovarian tumor epithelial and stromal cells after platinum-based chemotherapy. Chekerov R; Klaman I; Zafrakas M; Könsgen D; Mustea A; Petschke B; Lichtenegger W; Sehouli J; Dahl E Neoplasia; 2006 Jan; 8(1):38-45. PubMed ID: 16533424 [TBL] [Abstract][Full Text] [Related]
19. [Expression of AIB1 protein in epithelial ovarian cancer cells and its impact on apoptosis]. Han XY; Chen Y; Hou MM; Zhang J; Yang KX; Chen YY; Qie MR Sichuan Da Xue Xue Bao Yi Xue Ban; 2008 Jul; 39(4):619-22, 634. PubMed ID: 18798508 [TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant chemotherapy for epithelial ovarian cancer--role of apoptosis. Dutta T; Sharma H; Kumar L; Dinda AK; Kumar S; Bhatla N; Singh N Cancer Chemother Pharmacol; 2005 Oct; 56(4):427-35. PubMed ID: 15906030 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]